Cargando…
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI
Coagulation factor XI (FXI) is a novel target for antithrombotic therapy addressed by various therapeutic modalities currently in clinical development. The expected magnitude of thrombotic event reduction mediated by targeting FXI is unclear. METHODS—: We analyzed the association of 2 common genetic...
Autores principales: | Georgi, Benjamin, Mielke, Johanna, Chaffin, Mark, Khera, Amit V., Gelis, Lian, Mundl, Hardi, van Giezen, J.J.J., Ellinor, Patrick, Kathiresan, Sekar, Ziegelbauer, Karl, Freitag, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824502/ https://www.ncbi.nlm.nih.gov/pubmed/31558144 http://dx.doi.org/10.1161/STROKEAHA.119.026545 |
Ejemplares similares
-
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
por: Khera, Amit V., et al.
Publicado: (2018) -
Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
por: Husted, Steen, et al.
Publicado: (2009) -
Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease
por: Biddinger, Kiran J., et al.
Publicado: (2022) -
Importance of Baseline Specification in Evaluating Conservation Interventions and Achieving No Net Loss of Biodiversity
por: Bull, J W, et al.
Publicado: (2014) -
Armillifer-Infected Snakes Sold at Congolese Bushmeat Markets Represent an Emerging Zoonotic Threat
por: Hardi, Richard, et al.
Publicado: (2017)